Síndrome metabólico y litiasis urinaria de ácido úrico

  1. Lancina Martín, Juan Alberto
  2. Portela Pereira, Paula
  3. Vázquez-Martul Pazos, Darío
  4. López García, Daniel
  5. Sánchez Merino, José María
  6. Aller Rodríguez, Marcos
  7. Lamas Meilán, Cipriano
  8. Rey Fraga, Dolores
Revista:
Actualidad médica

ISSN: 0365-7965

Ano de publicación: 2013

Tomo: 98

Número: 788

Páxinas: 22-26

Tipo: Artigo

DIALNET GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Actualidad médica

Resumo

Introducción: Estudios epidemiológicos han puesto de manifiesto la asociación de urolitiasis con una serie de enfermedades de reconocido riesgo cardiovascular como la diabetes mellitus tipo 2, hipertensión arterial y síndrome metabólico. Es nuestro objetivo determinar la frecuencia del síndrome metabólico en una serie de pacientes diagnosticados en nuestro Servicio de cálculos de ácido úrico. Material y métodos: Se incluye un total de 71 pacientes diagnosticados de litiasis de ácido úrico, 46 varones y 25 mujeres, con una edad media de 62,4 años. La lateralidad y localización del cálculo se confirma por ecografía y/o tomografía axial computerizada. Se establece el diagnóstico del síndrome metabólico siguiendo los criterios propuestos por el NCEP-ATP III. Se realiza análisis estadístico con test de chi-cuadrado aplicando corrección de Yates. Resultados: Se observó síndrome metabólico en 49 pacientes (69,0%), muy por encima del 31% de la frecuencia reportada para la población española (p<0.0001). Además se comprobó descenso de HDL-colesterol sérico en 59 pacientes (83,1%), obesidad abdominal en 48 (67,8%), hipertensión arterial en 46 (64,8%), hipertrigliceremia en 39 (54,9%) e hiperglucemia en 31 (43,7%), mostrando todos estos factores diferencias estadísticamente significativas en relación con los datos registrados para la población general española. Conclusiones: Existe una marcada relación entre litiasis de ácido úrico y síndrome metabólico, como también para cada uno de los factores que constituyen el síndrome metabólico, con porcentajes que están muy por encima de su frecuencia poblacional registrada en España.

Referencias bibliográficas

  • Abate N, Chandalla M, Cabo-Chan AV, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestations of insulin resistance. Kidney Int. 2004; 65:386-92.
  • Akoudad S, Szklo M, McAdams Ma et al. Correlates of kidney stone disease differ by race in a multi-ethnic middle-aged population: the ARIC study. Prev Med. 2010; 51: 416-20.
  • Binbay M, Yuruk E, Akman T et al. Updated epidemiologic study of urolithiasis in Turkey II: role of metabolic syndrome components on urolithiasis. Urol Res. 2012; 40: 247–52.
  • Bobulescu IA, Dubree M, Zhang J, McLeroy P, Moe OW. Effect of renal lipid accumulation on proximal tubule Na+/H+ exhance and ammonium secretion. Am J Physiol Renal Physiol. 2008; 294: F1315-22.
  • Borghi L, Meshi T, Guerra A et al. Essential arterial hypertension and stone disease. Kidney Int. 1999; 55: 2397-406.
  • Cameron MA, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol. 2006; 17: 1422-8.
  • Cappuccio FP, Siani A, Barba G et al. A prospective study of hypertension and the incidence of kidney stones in men. J Hypertens. 1999; 17: 1017-22.
  • Cappuccio FP, Strazzullo P, Mancini M. Kidney stones and hypertension: population based study of an independent clinical association. BMJ. 1990; 300: 1234-6.
  • Chang IH, Lee YT, Lee DM et al. Metabolic syndrome, urine pH, and time-dependent risk of nephrolithiasis in korean men without hypertension and diabetes. Urology. 2011; 78: 753-8.
  • Cheung BM, Li C. Diabetes and hypertension: is there a common metabolic pathway?. Curr Atheroscler Rep. 2012; 14: 160-6.
  • Cho ST, Jung SI, Myung SC, Kim TH. Correlation of metabolic syndrome with urinary stone composition. Int J Urol. 2013; 20: 208-13.
  • Chobanian MC, Hammerman MR. Insulin stimulates ammoniagenesis in canine renal proximal tubular segments. Am J Physiol. 1987; 253: F1171-7.
  • Chung SD, Liu SP, Keller J, Lin HC. Urinary calculi and an increased risk of stroke: a population-based follow-up study. BJU Int. 2012; 110: E1053-9.
  • Cirillo M, Laurenzi N. Elevated blood pressure and positive history of kidney stones: results from a population-based study. J Hypertens. 1988; Suppl 6: S485.
  • Cupisti A, Morelli E, Meola M, Cozza V, Parrucci M, Barsotti G. Hypertension in kidney stone patients. Nephron. 1996; 73: 569-72.
  • Curhan CG, Willet WC, Rimm EB, Speizer FE, Stampfer MJ. Body size and risk of kidney stones. J Am Soc Nephrol. 1998; 9: 1645-52.
  • Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urol Res. 2006; 34: 193-9.
  • Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol. 2006; 17: 2026-33.
  • Domingos F, Serra A. Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. Nephrol Dial Transplant. 2011; 26:864-8.
  • Eckel RH, Grundt SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365: 1415-28.
  • Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney stone formers excrete more oxalate and have lower urine pH tha nondiabetic stone formers. J Urol. 2010; 183: 2244-8.
  • Eisner BH, Porten SP, Bechis SK, Stoller ML. Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis. J Urol. 2010; 183: 576-9.
  • Ekeruo WO, Tan YH, Young MD et al. Metabolic risk factors an the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol. 2004; 172: 159-63.
  • Fernández-Bergés D, Cabrera de León A, Sanz H et al. Síndrome metabólico en España: prevalencia y riesgo coronario asociado a la definición armonizada y a la propuesta por la OMS. Estudio DARIOS. Rev Esp Cardiol. 2012; 65: 241-8.
  • Filgueiras RD, Almeida JR, Kang HC, Rosa ML, Lugon JR. Metabolic syndrome and associated urolithiasis in adults enrolled in a community-based health program. Fam Pract. doi: 10.1093/fampra/cms075.
  • Gillen DL, Coe FL, Worcester EM. Nephrolithiasis and increased blood pressure among females with high body mass index. Am J Kidney Dis. 2005; 46: 263-9.
  • Grau M, Elosua R, Cabrera de León A et al. J. Factores de riesgo cardiovascular en España en la primera década del siglo XXI: análisis agrupado con datos individuales de 11 estudios de base poblacional, estudio DARIOS. Rev Esp Cardiol. 2011; 64: 295-304.
  • Hamano S, Kakatsu H, Suzuki N, Tomioka S, Tanaka M, Murakami S. Kidney stone disease and risk factors for cornary heart disease. Int J Urol. 2005; 12: 859-63.
  • Huang HS, Ma MC, Chen CF, Chen J. Lipid peroxidation and its correlation with urinary levels of oxalate, citric acid and osteopontin in patients with renal calcium oxalate stones. Urology. 2003; 62: 1123-8.
  • Inci M, Demirtas A, Sarli B, Akinsal E, Baydilli. Association between body mass index, liped profiles, and types of urinary stones. Renal Failure. 2012; 34: 1140-3.
  • Jeong, IG, Park J, Kang T et al. Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis. 2011; 58: 383-8.
  • Jung HS, Chang IH, Kim KD et al. Possible relationship between metabolic syndrome traits and nephrolithiasis: Incidence for 15 Years according to gender. Korean J Urol. 2011; 52: 548-53.
  • Khan SR. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome?. Urol Res. 2012; 40: 95-112.
  • Lemann J, Pleuss JA, Worcester EM et al. Urinary oxalate increases with body size and diseases with increasing dietary calcium intake among healthy adults. Kidney Int. 1996; 49: 200-8.
  • Lieske JC, De la Vega LS, Gettman MT et al. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis. 2006; 48: 897-904.
  • Losito A, Nunzi EF, Covarelli E, Nunzi E, Ferrara G. Increased acid excretion in kidney stone formers with esential hypertension. Nephrol Dial Transplant. 2009; 34: 137-41.
  • Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007; 2: 883-8.
  • Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010; 5: 1277-81.
  • Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004; 65:1422-5.
  • Madore F, Stampfer MJ, Rimm EB, Curhan CG. Nephrolithiasis and risk of hypertension. Am J Hypertens. 1998; 11: 46-53.
  • Madore F, Stampfer MJ, Willett WC, Speizer FE, Curhan CG. Nephrolithiasis an risk of hypertension in women. Am J Kidney. 1998; 32: 802-7.
  • Meydan N, Barutca S, Caliskan S, Camsari T. Urinary stone disease in diabetes mellitus. Scand J Urol Nephrol. 2003; 37: 64-70.
  • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143–3421.
  • Negri AL, Spivacow FR, Del Valle EE, Forrester M, Rosende F, Pinduli I. Role of overweight and obesity on the urinary excretion of promoters and inhibitors of stone formation in stone formers. Urol Res. 2008; 36: 303-7.
  • Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipedemia, and metabolic syndrome with obesity: Findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008; 207: 928-34.
  • Pak CY, Sakhaee K, Moe O et al. Biochemical profile of stoneforming patients with diabetes mellitus. Urology. 2003; 61: 523-7.
  • Raynal G, Achkar K, El Samad R, Kikassa JC, Jorest R. Cardiovascular risk associated with urolithiasis. Prog Urol. 2008; 18:288-91.
  • Reiner AP, Kahn A, Eisner BH et al. Kidney stones and subclinical atherosclerosis in young adults: The CARDIA study. J Urol. 2011; 186: 920-5.
  • Rendina D, De Filippo G, Zampa G, Muscariello R, Mossetti G, Strazzullo, P. Characteristic clinical and biochemical profile of recurrent calcium-oxalate nephrolithiasis in patients with metabolic syndrome. Nephrol Dial Transplant. 2011; 26: 2256-63
  • Rendina D, Mossetti G, De Filippo G et al: Association between metabolic syndrome and nephrolithiasis in an inpatient population in southern Italy: role of gender, hypertension and abdominal obesity. Nephrol Dial Transplant. 2009; 24: 900-6.
  • Rule AD, Roger VL, Melton LJ et al. Kidney stones associate with increased risk for myocardial infaction. J Am Soc Nephrol. 2010; 21:1641- 4.
  • Sakhaee K, Capolongo G, Maalouf NM et al. Metabolic syndrome and the risk of calcium stones. Nephrol Dial Transplant. 2012; 27: 3201-9.
  • Sakhaee K, Maalouf NM: Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol. 2008; 28: 174-80.
  • Schleicher MM, Reis MC, Costa SS, Rodrigues MP, Casurali LA. Patients with nephrolithiais and blood hypertension have higher calciuria tha those with isolated nephrolithiasis or hypertension?. Minerva Urol Nephrol. 2009; 61: 9-15.
  • Siener R, Glatz S, Nicolay C, Hesse A. The role of overweight and obesity in calcium oxalate stone formation. Obes Res 2004; 12: 106-13.
  • Strazzullo P, Barba G, Vuotto P et al. Past history of nephrolithiasis and incidence of hypertension in men: a reappraisal based on the results of the Olivetti Prospective Heart Study. Nephrol Dial Transplant. 2001; 16: 2232-5.
  • Strohmaier WL, Wrobel BM, Schubert G. Overweight, insulin resistance and blood pressure (parameters of the metabolic syndrome) in uric acid urolithiasis. Urol Res. 2012; 40: 171-5.
  • Taylor EN, Curhan GC. Body size and 24-hour urine composition. Am J Kidney Dis. 2006; 48: 905-15.
  • Taylor EN, Fung TT, Curhan CG. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol. 2009; 20: 2253-9.
  • Taylor EN, Mount DB, Forman JP, Curhan CG. Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate and other factors. Am J Kidney Dis. 2006; 47: 780-9.
  • Taylor EN, Stampfer MJ, Curhan CG. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005; 68: 1230-5.
  • Taylor EN, Stampfer MJ, Curhan CG. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005; 293:455-62.
  • Tiblin G. A population study of 50-year-old men. An analysis of the non-participation group. Acta Med Scand. 1965; 178: 453.
  • Tobili JE, Ferder L, Stella I, De Cavanaugh EM, Angerosa M, Inserra F. Effects fo angiotensin II subtype I receptor blockade by losartan on tubulo intestitial lesions caused by hyperoxaluria. J Urol. 2002; 168: 1550-5.
  • Tsao KC, Wu TL, Chang PY, Sun CF, Wu LL, Wu JT. Multiple risk markers for atherogenesis associated with chronic inflamation are detectable in patients with renal stones. J Clin Lab Anal. 2007; 21: 426-31.
  • Vinay P, Lemieux G, Cartier P, Ahmad M. Effect of fatty acids on renal ammoniogenesis in in vivo and in vitro studies. Am J Physiol. 1976; 231: 880-7.
  • Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007; 2: 550-6.
  • West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: The National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis. 2008; 51: 741-7.
  • Wrobel BM, Schubert G, Hörmann M, Strohmaier WL. Overweight and obesity: risk factors in calcium oxalate stone disease?. Avd Urol. doi: 10.1155/2012/438707.
  • Zimmerer T, Weiss C, Hammes HP et al. Evaluaton of urolithiasis: a link between stone formation and diabetes mellitus?. Urol Int. 2009; 82: 350-5.
Fonte de datos: Dialnet